Bristol-Myers Squibb Company (NYSE: BMY) Stock Competitors & Peer Comparison
See BMY's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BMY and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BMY | $62.14 | -1.57% | 127.1B | 10.48 | $5.93 | +4.04% |
| LLY | $1,354.00 | -0.79% | 1.3T | 43.57 | $31.49 | +0.49% |
| JNJ | $276.22 | +1.43% | 664.8B | 25.74 | $10.73 | +1.92% |
| ABBV | $291.31 | +1.07% | 514.9B | 28.59 | $10.19 | +2.39% |
| MRK | $146.73 | -0.14% | 362B | 45.70 | $3.21 | +2.32% |
| NVS | $162.55 | +0.38% | 307B | 18.71 | $8.69 | +2.93% |
| AZN | $186.43 | -0.22% | 289.1B | 20.13 | $9.26 | +1.74% |
| AMGN | $460.42 | +0.03% | 248.8B | 20.57 | $22.37 | +2.16% |
| GILD | $166.89 | -0.41% | 206.9B | -427.74 | -$0.39 | +1.94% |
| NVO | $40.31 | +0.02% | 177.7B | 10.03 | $4.02 | +4.46% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
BMY vs LLY Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, LLY has a market cap of 1.3T. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while LLY trades at $1,354.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas LLY's P/E ratio is 43.57. In terms of profitability, BMY's ROE is +0.44%, compared to LLY's ROE of +0.84%. Regarding short-term risk, BMY is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for BMY.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
BMY vs JNJ Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, JNJ has a market cap of 664.8B. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while JNJ trades at $276.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas JNJ's P/E ratio is 25.74. In terms of profitability, BMY's ROE is +0.44%, compared to JNJ's ROE of +0.20%. Regarding short-term risk, BMY is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for BMY.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
BMY vs ABBV Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, ABBV has a market cap of 514.9B. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while ABBV trades at $291.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas ABBV's P/E ratio is 28.59. In terms of profitability, BMY's ROE is +0.44%, compared to ABBV's ROE of -2.03%. Regarding short-term risk, BMY is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for BMY.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
BMY vs MRK Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, MRK has a market cap of 362B. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while MRK trades at $146.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas MRK's P/E ratio is 45.70. In terms of profitability, BMY's ROE is +0.44%, compared to MRK's ROE of +0.05%. Regarding short-term risk, BMY is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for BMY.Check MRK's competition here
Novartis AG (NYSE: NVS)
BMY vs NVS Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, NVS has a market cap of 307B. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while NVS trades at $162.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas NVS's P/E ratio is 18.71. In terms of profitability, BMY's ROE is +0.44%, compared to NVS's ROE of +0.25%. Regarding short-term risk, BMY is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for BMY.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
BMY vs AZN Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, AZN has a market cap of 289.1B. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while AZN trades at $186.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas AZN's P/E ratio is 20.13. In terms of profitability, BMY's ROE is +0.44%, compared to AZN's ROE of +0.22%. Regarding short-term risk, BMY is less volatile compared to AZN. This indicates lower risk in terms of short-term price fluctuations for BMY.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
BMY vs AMGN Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, AMGN has a market cap of 248.8B. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while AMGN trades at $460.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas AMGN's P/E ratio is 20.57. In terms of profitability, BMY's ROE is +0.44%, compared to AMGN's ROE of +0.86%. Regarding short-term risk, BMY is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for BMY.Check AMGN's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
BMY vs GILD Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, GILD has a market cap of 206.9B. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while GILD trades at $166.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas GILD's P/E ratio is -427.74. In terms of profitability, BMY's ROE is +0.44%, compared to GILD's ROE of -0.22%. Regarding short-term risk, BMY is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for BMY.Check GILD's competition here
Novo Nordisk A/S (NYSE: NVO)
BMY vs NVO Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, NVO has a market cap of 177.7B. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while NVO trades at $40.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas NVO's P/E ratio is 10.03. In terms of profitability, BMY's ROE is +0.44%, compared to NVO's ROE of +0.54%. Regarding short-term risk, BMY is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for BMY.Check NVO's competition here
Pfizer Inc. (NYSE: PFE)
BMY vs PFE Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, PFE has a market cap of 167.5B. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while PFE trades at $29.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas PFE's P/E ratio is 9.63. In terms of profitability, BMY's ROE is +0.44%, compared to PFE's ROE of +0.05%. Regarding short-term risk, BMY is less volatile compared to PFE. This indicates lower risk in terms of short-term price fluctuations for BMY.Check PFE's competition here
Sanofi (NASDAQ: SNY)
BMY vs SNY Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, SNY has a market cap of 113.7B. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while SNY trades at $47.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas SNY's P/E ratio is 10.24. In terms of profitability, BMY's ROE is +0.44%, compared to SNY's ROE of +0.06%. Regarding short-term risk, BMY is less volatile compared to SNY. This indicates lower risk in terms of short-term price fluctuations for BMY.Check SNY's competition here
GSK plc (NYSE: GSK)
BMY vs GSK Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, GSK has a market cap of 101.8B. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while GSK trades at $50.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas GSK's P/E ratio is 10.87. In terms of profitability, BMY's ROE is +0.44%, compared to GSK's ROE of +0.23%. Regarding short-term risk, BMY is less volatile compared to GSK. This indicates lower risk in terms of short-term price fluctuations for BMY.Check GSK's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
BMY vs CELG-RI Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, CELG-RI has a market cap of 94.8B. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while CELG-RI trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, BMY's ROE is +0.44%, compared to CELG-RI's ROE of +0.44%. Regarding short-term risk, BMY is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for BMY.Check CELG-RI's competition here
Biogen Inc. (NASDAQ: BIIB)
BMY vs BIIB Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, BIIB has a market cap of 36.7B. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while BIIB trades at $248.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas BIIB's P/E ratio is 15.69. In terms of profitability, BMY's ROE is +0.44%, compared to BIIB's ROE of +0.02%. Regarding short-term risk, BMY is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for BMY.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
BMY vs HZNP Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas HZNP's P/E ratio is 61.86. In terms of profitability, BMY's ROE is +0.44%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, BMY is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for BMY.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
BMY vs GRFS Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, GRFS has a market cap of 7.1B. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while GRFS trades at $8.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas GRFS's P/E ratio is 9.69. In terms of profitability, BMY's ROE is +0.44%, compared to GRFS's ROE of +0.09%. Regarding short-term risk, BMY is less volatile compared to GRFS. This indicates lower risk in terms of short-term price fluctuations for BMY.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
BMY vs OGN Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while OGN trades at $13.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas OGN's P/E ratio is 4.13. In terms of profitability, BMY's ROE is +0.44%, compared to OGN's ROE of +0.22%. Regarding short-term risk, BMY is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for BMY.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
BMY vs AMRN Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, AMRN has a market cap of 241.1M. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while AMRN trades at $11.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas AMRN's P/E ratio is -116.55. In terms of profitability, BMY's ROE is +0.44%, compared to AMRN's ROE of -0.04%. Regarding short-term risk, BMY is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for BMY.Check AMRN's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
BMY vs MIRA Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, MIRA has a market cap of 23.3M. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while MIRA trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas MIRA's P/E ratio is -0.38. In terms of profitability, BMY's ROE is +0.44%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, BMY is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for BMY.Check MIRA's competition here
Scilex Holding Company (NASDAQ: SCLX)
BMY vs SCLX Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, SCLX has a market cap of 11.7M. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while SCLX trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas SCLX's P/E ratio is -0.04. In terms of profitability, BMY's ROE is +0.44%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, BMY is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for BMY.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
BMY vs SCLXW Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, SCLXW has a market cap of 7.6M. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while SCLXW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas SCLXW's P/E ratio is N/A. In terms of profitability, BMY's ROE is +0.44%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, BMY is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for BMY.Check SCLXW's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
BMY vs BDSIW Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, BMY's ROE is +0.44%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, BMY is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for BMY.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
BMY vs CRXT Comparison November 2026
Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BMY stands at 127.1B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, BMY is priced at $62.14 on the NYSE, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BMY currently has a P/E ratio of 10.48, whereas CRXT's P/E ratio is -0.02. In terms of profitability, BMY's ROE is +0.44%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, BMY is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for BMY.Check CRXT's competition here